MDR1 and MRP1 transporters could reduce the intracellular accumulation of chemotherapeutic agents in tumor cells by mediating drug efflux, which can reduce HCC patients' sensitivity to drugs such as regorafenib [85, 86]. Here, ABCB1 is linked to neoplasm.